iQ-007

iQure Australia Pty Ltd · Phase 1 active Small molecule

At a glance

Generic name	iQ-007
Sponsor	iQure Australia Pty Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

iQ-007 CI brief — competitive landscape report
iQ-007 updates RSS · CI watch RSS
iQure Australia Pty Ltd portfolio CI